It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Infantile hemangiomas (IHs) are the most common benign tumors in early childhood. They show a distinctive mechanism of tumor growth in which a rapid proliferative phase is followed by a regression phase (involution). Propranolol is an approved treatment for IHs, but its mechanism of action remains unclear. We integrated and harmonized microRNA and mRNA transcriptome data from newly generated microarray data on IHs with publicly available data on toxicological transcriptomics from propranolol exposure, and with microRNA data from IHs and propranolol exposure. We identified subsets of putative biomarkers for proliferation and involution as well as a small set of putative biomarkers for propranolol’s mechanism of action for IHs, namely EPAS1, LASP1, SLC25A23, MYO1B, and ALDH1A1. Based on our integrative data approach and confirmatory experiments, we concluded that hypoxia in IHs is regulated by EPAS1 (HIF-2α) instead of HIF-1α, and also that propranolol-induced apoptosis in endothelial cells may occur via mitochondrial stress.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Arkansas for Medical Sciences, Department of Biomedical Informatics, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
2 Mesquite Rehabilitation Institute, Mesquite, USA (GRID:grid.241054.6)
3 University of Arkansas for Medical Sciences, Department of Otolaryngology, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637)
4 Department of Surgery, New York-Presbyterian/Morgan Stanley Children’s Hospital, Columbia University, New York, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
5 Columbia University, New York, Department of Reproductive Sciences in Obstetrics & Gynecology and Surgery, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
6 University of Arkansas for Medical Sciences, Department of Otolaryngology, Little Rock, USA (GRID:grid.241054.6) (ISNI:0000 0004 4687 1637); Arkansas Children’s Hospital, Little Rock, USA (GRID:grid.239305.e) (ISNI:0000 0001 2157 2081)